GRN and Alzheimer disease: The second GWAX/GWAS expanded the study subjects to 1,126,563 that included 90,338 (46,613 proxy) AD cases and 1,036,225 (318,246 proxy) controls and reported 38 loci [76], including 7 novel loci ((AGRN, TNIP1, HAVCR2, TMEM106B, GRN, NTN5, LILRB2).